These data reveal that orally dosed EC-70124 inhibits FLT3-ITDMUT AML cell growth in vivo, but withdrawal of the inhibitor results in leukemia relapse, suggesting that outgrowth of EC-70124 resistant cells. Here, FLT3 is linked to acute myeloid leukemia.